ATE417054T1 - Steuerbare phosphofructokinase und der warburg effekt - Google Patents

Steuerbare phosphofructokinase und der warburg effekt

Info

Publication number
ATE417054T1
ATE417054T1 AT98957451T AT98957451T ATE417054T1 AT E417054 T1 ATE417054 T1 AT E417054T1 AT 98957451 T AT98957451 T AT 98957451T AT 98957451 T AT98957451 T AT 98957451T AT E417054 T1 ATE417054 T1 AT E417054T1
Authority
AT
Austria
Prior art keywords
ipfk
phosphofructokinase
controllable
warburg effect
cancer
Prior art date
Application number
AT98957451T
Other languages
English (en)
Inventor
Richard Bucala
Jason A Chesney
Robert A Mitchell
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Application granted granted Critical
Publication of ATE417054T1 publication Critical patent/ATE417054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
AT98957451T 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt ATE417054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/961,578 US6413939B1 (en) 1997-10-31 1997-10-31 Inducible phosphofructokinase and the Warburg effect

Publications (1)

Publication Number Publication Date
ATE417054T1 true ATE417054T1 (de) 2008-12-15

Family

ID=25504669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957451T ATE417054T1 (de) 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt

Country Status (10)

Country Link
US (4) US6413939B1 (de)
EP (1) EP1042350B1 (de)
JP (1) JP4369044B2 (de)
AT (1) ATE417054T1 (de)
AU (1) AU1370799A (de)
CA (1) CA2308091A1 (de)
DE (1) DE69840342D1 (de)
ES (1) ES2319345T3 (de)
IL (1) IL135887A0 (de)
WO (1) WO1999023108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0216097D0 (en) * 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP1656376A1 (de) * 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituierte naphthyridinderivate als inhibitoren von macrophage migration inhibitory factor und deren verwendung bei der behandlung von menschlichen krankheiten
US20060166236A1 (en) * 2004-12-15 2006-07-27 Chong-Sheng Yuan Allosteric enzyme coupled immunoassay (AECIA)
EP1861407A1 (de) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinonderivate als hemmer des makrophagenmigrationshemmfaktors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8662667B2 (en) * 2007-12-21 2014-03-04 Carl Zeiss Meditec Ag Ophthalmologic visualization system
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
WO2012040108A2 (en) * 2010-09-20 2012-03-29 Caliper Life Sciences Multivalent fluorescent probes
EP2532747B1 (de) * 2011-06-09 2015-12-02 Deutsches Krebsforschungszentrum Modulatoren von Glycerin-3-phosphatdehydrogenase (GPD2) zur Therapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015674A1 (en) * 1995-10-24 1997-05-01 Garvan Institute Of Medical Research Progestin-regulated gene
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect

Also Published As

Publication number Publication date
US6255046B1 (en) 2001-07-03
DE69840342D1 (de) 2009-01-22
IL135887A0 (en) 2001-05-20
US20030228568A1 (en) 2003-12-11
EP1042350A4 (de) 2003-01-02
US6413939B1 (en) 2002-07-02
WO1999023108A9 (en) 1999-08-19
ES2319345T3 (es) 2009-05-06
WO1999023108A1 (en) 1999-05-14
JP4369044B2 (ja) 2009-11-18
EP1042350B1 (de) 2008-12-10
AU1370799A (en) 1999-05-24
JP2001521731A (ja) 2001-11-13
EP1042350A1 (de) 2000-10-11
US6596851B1 (en) 2003-07-22
CA2308091A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
DE69840342D1 (de) Steuerbare phosphofructokinase und der warburg effekt
Jacobi et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
BG103965A (en) QUINOLINE AND QUINOXALINE COMPOUNDS INHIBITING THE RECEIVED FROIM THROMBOCYTES FACTOR OF GROWTH AND/OR P561ck THYROSINEKINASES
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
HUP0102661A2 (hu) BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
EA199900349A1 (ru) Каталитическая субъединица теломеразы человека
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
CA2362917A1 (en) Methods for anti-tumor therapy
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
WO2001085219A3 (en) Identification, diagnosis, and treatment of breast cancer
DE69330137D1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
HUP0300007A2 (en) Antibody with specificity for colon cancer
Li et al. Plant sterols as selective DNA polymerase β lyase inhibitors and potentiators of bleomycin cytotoxicity
Gallo et al. Reverse transcriptase from Mason-Pfizer monkey tumor virus, avian myeloblastosis virus, and Rauscher leukemia virus and its response to rifamycin derivatives
DE69534197D1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
Burger et al. Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119)
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
ATE240100T1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
Hightower et al. In vitro evaluation of the novel chemotherapeutic agents U-73, 975, U-77, 779, and U-80, 244 in gynecologic cancer cell lines
FR2654106B1 (fr) Derives phosphores de cytosine, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042350

Country of ref document: EP